For biotech startups and emerging sponsors, the Pre-Investigational New Drug (Pre-IND) meeting is a pivotal opportunity to align with the FDA before launching clinical trials.
For biotech companies aiming to initiate human clinical trials, filing an Investigational New Drug (IND) application is a pivotal milestone. But before the FDA greenlights
Cell and gene therapies represent the cutting edge of biotech innovation—but their regulatory pathways are anything but straightforward. Filing an Investigational New Drug (IND) application
Developing therapies for rare diseases presents both a noble mission and a unique regulatory challenge. With fewer patients, limited precedent, and evolving FDA guidance, biotech
As biotech innovation accelerates, the FDA’s expectations for Investigational New Drug (IND) applications continue to evolve. In 2025, sponsors must navigate updated regulatory guidance, digital
For biotech companies preparing an Investigational New Drug (IND) application, the Investigator’s Brochure (IB) is more than a formality, it’s a cornerstone of regulatory communication.
As biotech firms prepare to submit Investigational New Drug (IND) applications, understanding the FDA’s electronic Common Technical Document (eCTD) format is no longer optional, it’s
For biotech companies preparing to file an Investigational New Drug (IND) application, Chemistry, Manufacturing, and Controls (CMC) documentation is a critical pillar of regulatory success.